| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
CASI Pharmaceuticals, Inc.
13D/A
CASIF · G1933S101
|
4.8% |
1/20/2026
Event 9/30/2025
|
||||
| IDG-Accel China Growth Fund III L.P. | 4.5% | |||||
| IDG-Accel China III Investors L.P. | 4.5% | |||||
| IDG-Accel China Growth Fund III Associates L.P. | 4.5% | |||||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 4.5% | |||||
| Ho Chi Sing | 4.5% | |||||
| Zhou Quan | 4.8% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Pony AI Inc.
13G
PONY · 732908108
|
4.3% |
11/12/2025
Event 9/30/2025
|
||||
| IDG China Venture Capital Fund IV L.P. | 4.3% | |||||
| IDG China IV Investors L.P. | 4.3% | |||||
| IDG China Capital Fund III L.P. | 4.3% | |||||
| IDG China Capital III Investors L.P. | 4.3% | |||||
| IDG China Venture Capital Fund IV Associates L.P. | 4.3% | |||||
| IDG China Venture Capital Fund GP IV Associates Ltd. | 4.3% | |||||
| IDG China Capital Fund III Associates L.P. | 4.3% | |||||
| IDG China Capital Fund GP III Associates Ltd. | 4.3% | |||||
| Zhou Quan | 4.3% | |||||
| Ho Chi Sing | 4.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.